THERAPY DOSSIER · th-14002e6c83b5

Nicaraven (N,N'-(1-methyl-1,2-ethanediyl)bis-3-pyridinecarboxamide)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL1705525 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Nicaraven; Antevas
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23555869 ↗2013Reported benefit

Nicaraven attenuates radiation-induced injury in hematopoietic stem/progenitor cells in mice.

MouseRadiationC57BL/6Malen = 12 mice (6 nicaraven, 6 placebo)Intraperitoneal100 mg/kg/dayGiven soon after each of the five daily radiation exposures

Model: Whole-body gamma-ray irradiation, 1 Gy daily for 5 successive days (total 5 Gy) from a caesium source at 0.86 Gy/min

Post-radiation nicaraven increased peripheral nucleated cells and c-kit and CD34 positive cells, increased bone marrow colony formation, reduced 53BP1 foci and lowered urinary 8-OHdG and plasma IL-6 and TNF-alpha, although intracellular and mitochondrial reactive oxygen species and plasma 8-OHdG di…

Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…